Gene therapy for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy, EXG202, given as an injection into the eye. It aims to see if the treatment is safe and can help slow vision loss from wet AMD, a condition where abnormal blood vessels leak fluid under the retina.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have wet age-related macular degeneration (AMD) with active, leaking blood vessels in the eye being studied.
- Your eye doctor can get a clear picture of the back of your eye to confirm the diagnosis.
- You agree to use effective birth control during the study and not to donate sperm or eggs.
- You are willing and able to follow the study rules and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, EXG202, injected into the eye to treat wet age-related macular degeneration (wAMD). It is for people who have already had some benefit from standard treatments in the past 6 months.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a new CRISPR-based gene therapy injected into the eye to treat wet age-related macular degeneration (AMD). It aims to stop the growth of abnormal blood vessels that damage your vision.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This trial tests a new gene therapy called LX109 for wet age-related macular degeneration (nAMD). It is for patients who still need regular anti-VEGF injections, and the treatment aims to reduce how often you need those injections.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.